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Abstract: Experimental therapeutics developed to exploit RNA interference (RNAi) are now in
clinical studies. Here, the translation from concept to clinic for the first experimental therapeutic
to provide targeted delivery of synthetic, small interfering RNA (siRNA) in humans is described.
This targeted, nanoparticle formulation of siRNA, denoted as CALAA-01, consists of a cyclo-
dextrin-containing polymer (CDP), a polythethylene glycol (PEG) steric stabilization agent, and
human transferrin (Tf) as a targeting ligand for binding to transferrin receptors (TfR) that are
typically upregulated on cancer cells. The four component formulation is self-assembled into
nanoparticles in the pharmacy and administered intravenously (iv) to patients. The designed
features of this experimental therapeutic are described, and their functions illustrated.
Keywords: CALAA-01; siRNA; targeted delivery; targeted nanoparticle; clinical trial
Introduction
The development of new therapeutics that attempt to
engage a RNAi pathway has opened a new area of drug
discovery and development. Traditional drug discovery and
development involve large scale screenings of small molecule
libraries with initial screening hits subjected to subsequent
medicinal chemistry approaches to create enhanced versions.
Translation of small molecule experimental therapeutics into
the clinic has led to high failure rates for a variety of reasons
that include lack of efficacy, poor pharmacokinetics (PK),
and so on. Drug discovery and development utilizing RNAi-
based mechanisms allow for significantly different strategies
than those utilized in traditional drug discovery and develop-
ment methodologies. They have the potential to provide
therapies for many targets that are currently undruggable and
to do so with higher success rates in the clinic.
While there are many ways to engage RNAi pathways,
the majority of the clinical trials currently being conducted
involve small interfering RNA (siRNA). The initial clinical
trials employ naked siRNA that is administered locally (to
the eye, lung, or skin).1 The first clinical trial to use
systemically administered, naked siRNA is for the treatment
of acute renal failure (see www.clinicaltrials.gov for details).
Systemically injected, naked siRNA clears quickly through
the kidney (within minutes), so this method of administration
is much like a “local” administration to the kidney. The naked
siRNA may or may not be chemically modified to impart
stability and modulate immunostimulatory effects (there are
trials using both types of naked siRNA). In 2008, the first
targeted delivery of siRNA was accomplished in a human.
A phase I trial using the experimental therapeutic CALAA-
01 was initiated, and the first patient was treated in May of
2008. This targeted nanoparticle is administered intrave-
nously (iv) for the treatment of solid tumors. Here, I provide
the historical development of CALAA-01 (Calando Phar-
maceuticals-01) from the design concepts to its clinical
application.
Design of a Targeted Delivery System for
Nucleic Acids
Delivery systems for nucleic acids that engage the RNAi
pathway have benefited from previous work on delivery
systems for other nucleic acids such as plasmids (pDNA),* Mailing address: Chemical Engineering, California Institute of
Technology, Mail Code 210-41, Pasadena, CA 91125. E-mail:
mdavis@cheme.caltech.edu. Telephone: 626-395-4251. Fax:
626-568-8743.
(1) Edbrooke, M.; Clarke, N. RNAi therapeutics: addressing targets.
Eur. Pharm. ReV. 2008, 4, 11–17.
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oligonucleotides, ribozymes, and DNAyzmes. While there
are differences when delivering each of these classes of
nucleic acids, there are also common features. We began
work in 1996 to develop a targeted delivery system for the
systemic administration of nucleic acids. Our objective was
to create new experimental therapeutics for the treatment of
cancer. The methodology that was taken can be described
as a systems approach to the design and engineering of a
multifunctional colloidal particle. When the work was
initiated, the terminology “nanoparticle” was not generally
used. However, this notation has quickly been adopted for
colloids in the range of 1-100 nm in diameter, and I will
stay with this notation here.
My initial schematic to illustrate the desired concept of a
targeted, multifunctional nanoparticle is reproduced in Figure
1 (the first schematic presented in the U.S. provisional patent
application). Issues from this initial design that have been
carried through to the clinic in 2008 are (i) the use of a
cyclodextrin-containing polymer (CDP) formulation that
assembles with nucleic acids to give small colloidal particles
(nanoparticles), (ii) the formulation of colloidal particles
(nanoparticles) having diameters at or below 100 nm, (iii)
the use of targeting ligands (R in Figure 1) to bind to cell
surface receptors and trigger endocytosis, and (iv) the
recognition of acidification as a mechanism to initiate
colloidal particle disassembly and escape from the endocytic
pathway. While the initial concept was illustrated for pDNA,
we realized at that time that the system could work for all
forms of nucleic acids, as the CDPs interact with the nucleic
acids by electrostatic charge and thus should be sequence-
and possibly size-independent.
In the mid-1990s, there were some guidelines for over-
coming extracellular and intracellular barriers with non-viral2
and cationic polymer-based3 delivery systems. One of the
most difficult issues that needed to be addressed was how
to create a multifunctional delivery system that could
accomplish many tasks at the right place and at the right
time. This integration of numerous functions was certainly
a limiting factor in the development of non-viral delivery
systems. Thus, a primary goal was to develop a fully
integrated system that would be capable of transitioning from
a research curiosity into an experimental therapeutic that
could be used in humans. The synthetic pathways developed
to create the components of the delivery system were all
defined so they could be scaled up at cGMP conditions.
Additionally, formulation methods took into consideration
the need for long-term stability. To begin, numerous design
issues were addressed. Tables 1 and 2 provide some of the
design issues and key features that were considered when
creating the targeted delivery system.
Over the course of the development of CALAA-01, there
were some modifications to these criteria as new data became
available. For example, particle diameters of ∼100 nm were
initially considered. After further work from our laboratory
as well as other literature reports, the particle diameters were
refined to smaller sizes,∼50-70 nm. This was due to further
understanding on requirements for particle movements in
tumors.
Finally, the delivery system ended up as a three-component
system (CDP, AD-PEG, and AD-PEG-Tf; see Figure 2a) that
was developed into a two-vial formulation where the delivery
components are contained in one vial and the siRNA in the
second vial (see Figure 2b). When the contents of the two
vials are combined, they self-assemble into ∼70 nm nano-
particles (see Figure 2b).
These targeted nanoparticles are administered iv to patients
where they circulate (too large to escape via the kidney) and
localize in tumors (see Figure 3). The transferrin (Tf) on
the nanoparticle is able to bind to transferrin receptors (TfR)
on cancer cells, and the nanoparticles can be internalized
via receptor-mediated endocytosis (Figure 3d). The CDP
contains organic groups that are protonated around pH ) 6.
This “chemical sensing” mechanism then triggers a number
of processes that provide escape from endocytic vesicles and
nanoparticle release of the nucleic acid into the cytoplasm.
Of importance is that each of the delivery components is
sufficiently small so that when the nanoparticle disassembles
into individual components, those components can be cleared
from the body via the kidney. Next, the delivery system, its
assembly, and its function will be described in detail.
Components of the Delivery System
CDP. The key to the success of the delivery system is the
cyclodextrin-containing polymer. This polymer provides
many functions to the overall delivery system. The CDP is
(2) Davis, M. E. Non-Viral Gene Delivery Systems. Curr. Opin.
Biotechnol. 2003, 13, 128–131.
(3) Hwang, S. J.; Davis, M. E. Cationic Polymers for Gene Delivery:
Designs for Overcoming Barriers to Systemic Administration.
Curr. Opin. Mol. Ther. 2001, 3, 183–191.
(4) Davis, M. E.; Pun, S. H.; Bellocq, N. C.; Reineke, T. M.;
Popielarski, S. R.; Mishra, S.; Heidel, J. D. Self-Assembling
Nucleic Acid Delivery Vehicles via Linear, Water-Soluble,
Cyclodextrin-Containing Polymers. Curr. Med. Chem. 2004, 11,
179–197.
Figure 1. Initial schematic of delivery system in 1996.
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a short polycation (see Figure 4 for basic structure, x is
typically around 5). The polycation assembles with nucleic
acids (polyanions) primarily via electrostatic interactions.
These interactions allow for assembly of the CDP with
different types and sizes of nucleic acids. The composite
CDP-nucleic acid structures are nanoparticles where the
nucleic acids are completely protected from nuclease deg-
radation. The cyclodextrins within the polymer chains that
ultimately reside on the surface of the nanoparticles are used
for assembling the steric stabilization agent (AD-PEG) and
the targeting agent (AD-PEG-Tf) as discussed below. Ad-
ditionally, the polymer backbone is used as a scaffold for
attaching agents (see, e.g., the imidazole groups in the
schematic of the CDP in Figure 2a) that assist in the
endocytic pathway escape and nucleic acid release (described
below).
Cyclodextrins are used in pharmaceutical formulations, and
as such, their long-term biocompatibilities are being defined
in humans.5 Because of the low toxicity, the lack of immune
stimulation, and the absence of enzyme degradation in
humans of cyclodextrins, they were chosen as one of the
building blocks for the CDP component. While numerous
types of cyclodextrin-containing polymers existed previous
to our work, for example, randomly cross-linked cyclodextrin
polymers and polymers with grafted cyclodextrins,5 the CDPs
presented here are a new class of polymers in that the
cyclodextrin is now part of the polymer backbone of a linear,
water-soluble polymer.5 The CDP polymers are synthesized
by a condensation polymerization between a difunctionalized
cyclodextrin comonomer and a second, difunctionalized
comonomer that contains the charge centers. Since both
comonomers are difunctionalized, the polymer formed from
their co-condensation is linear. The structure-functional
behavior of the CDP type polymers has been investigated
in detail,4,6-12 and only highlights will be presented here.
The basic structure of the linear, cyclodextrin-containing
polymers can be represented by the schematic shown in
Figure 4a. The CDP that was ultimately found to give the
(5) Davis, M. E.; Brewster, M. E. Cyclodextrin-based pharmaceutics:
Past, present, future. Nat. ReV. Drug DiscoVery. 2004, 3, 1023–
1035.
(6) Gonzalez, H.; Hwang, S. J.; Davis, M. E. A New Class of
Polymers for the Delivery of Macromolecular Therapeutics.
Bioconjugate Chem. 1999, 10, 1068–1074.
(7) Hwang, S. J.; Bellocq, N. C.; Davis, M. E. Effects of Structure
of -Cyclodextrin-Containing Polymers on Gene Delivery. Bio-
conjugate Chem. 2001, 12, 280–290.
(8) Reineke, T. M.; Davis, M. E. Structural Effects of Carbohydrate-
Containing Polycations on Gene Delivery. Part 1: Carbohydrate
Size and Its Distance from Charge Centers. Bioconjugate Chem.
2003, 14, 247–254.
(9) Reineke, T. M.; Davis, M. E. Structural Effects of Carbohydrate-
Containing Polycations on Gene Delivery. Part 2: Charge Center
Types. Bioconjugate Chem. 2003, 14, 255–261.
(10) Popielarski, S. R.; Mishra, S.; Davis, M. E. Structural Effects of
Carbohydrate-Containing Polycations on Gene Delivery. 3. Cy-
clodextrin Type and Functionalization. Bioconjugate Chem. 2003,
14, 672–678.
(11) Davis, M. E.; Bellocq, N. C. Cyclodextrin-Containing Polymers
for Gene Delivery. J. Inclusion Phenom. Macrocyclic Chem. 2003,
44, 17–22.
(12) Pun, S. H.; Davis, M. E. Cyclodextrin-Containing Polymers
for Gene Delivery. In Polymeric Gene DeliVery: Principles
and Applications; Amiji, M. M., Ed.; CRC Press: Boca Raton,
FL, 2004; pp 187-210.
Table 1. Design Issues Considered (Modified from ref 4)
design criteria advantages/comments
1. adaptability 1. can modify system in response to new mechanistic information
2. formulation with nucleic acids via self-assembly 2. ease of use and scale-up
3. formulation with any type of nucleic acid and/or combination 3. generality of deliverable, uses electrostatic interactions since
these are common to all nucleic acids
4. non-peptide-based 4. no possibility of MHC (major histocompatibility complex)
presentations
5. non-antigenic 5. enables repeat dosing
6. complete nucleic acid encapsulation 6. protection of nucleic acid from nucleases and Toll-like receptors
on cell surfaces; for example, TLR-3 recognizes double
stranded RNA
7. components of system nontoxic and of size to be cleared via
the kidney when delivery system disassembles
7. minimize toxicity and provide for excretion after disassembly
releases the nucleic acid at the target site
Table 2. Key Features of the Delivery System (Modified from ref 4)
features comments
1. particle size: larger than 10 nm but not larger than 75 ( 25 nm 1. injectable, minimizes renal clearance (must be larger than 10
nm), access to tumors, movement within tumors
2. particle surface charge: -10 mV to +10 mV 2. minimizes phagocytosis, avoids nonspecific interactions, avoids
self-aggregation
3. contains targeting ligand on particle surface 3. provides some selectivity for cell type and enhances uptake into
cells via receptor-mediated endocytosis
4. endocytic pathway escape mechanism and may also contain a
nuclear trafficking component
4. enhances delivery efficiencies, nuclear trafficking not necessary
with siRNA
First Targeted DeliVery of siRNA in Humans reviews
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best overall behavior is illustrated in Figure 4b, and its
relationship to the schematic in Figure 4a is provided.
Typically, these polycations have ∼5-6 repeating units (x
) 5, 6) and thus are low molecular weight polymers (can
be considered oligomers). This was accomplished by design
to provide low toxicity, minimal complement activation and
to permit renal clearance in animals and humans. The
structural variations investigated were (i) the type of cyclo-
dextrin (A in Figure 4),4,8,10,12 (ii) the absence of the
cyclodextrin (A in Figure 4) (other sugars4,8,12 and even
methylenes4,8,12 instead of sugars were explored), (iii) the
distance between the cyclodextrin and the charge center (S
in Figure 4),4,6,12 (iv) the type of charge center (C in Figure
4), for example, amidines, quarternary amines, and secondary
amines,4,9-12 and (v) the distance between the charge centers
(B in Figure 4).4,7 The structure-functional relationship
investigations primarily employed pDNA as the nucleic acid
being delivered. The overall conclusions obtained were (i)
the presence of the cyclodextrin gave the highest water
solubility and the lowest toxicity, (ii) the type of cyclodextrin
did not really affect the transfection properties (gene expres-
sion and toxicity) and beta-cyclodextrin was chosen because
it provided much better properties for large-scale processes
of collection and purification of the CDP over both alpha
and gamma cyclodextrin, (iii) when the distance between
the cyclodextrin and the charge center was small, the polymer
would not bind well to the nucleic acid (presumably due to
steric effects of the cyclodextrin), (iv) the further the distance
between the charge centers, the lower the cellular toxicity;
however, the binding to the nucleic acid also declined with
increasing distance, and (v) the amidine charge centers
provided for lower toxicity and better delivery efficacy.
Given these results, the CDP illustrated in Figure 4b provided
the best overall properties and was used as the polymer for
further formulations.
Nanoparticles formed from polymers and nucleic acids can
enter cells via endocytosis. In order to effectively deliver
the nucleic acid, the polymer must facilitate endocytic
pathway escape and release of the nucleic acid. Certain pH-
sensitive polymers such as polyethyleneimine (PEI) are said
Figure 2. Components and formulation of targeted nano-
particle-containing siRNA. (a) The delivery components
are (i) a water-soluble, linear cyclodextrin-containing poly-
mer (CDP), (ii) an adamantane (AD)-PEG conjugate (PEG
MW of 5000) (AD-PEG), and (iii) the targeting component
that is an adamantane conjugate of PEG (PEG MW of
5000) that has human transferrin (Tf) conjugated at the
end opposite to the adamantane (Tf-PEG-AD). (b) The for-
mulation contains two vials, one with siRNA and the other
with the delivery components. When the two vials are
mixed together, the targeted nanoparticles form via
self-assembly of the four components.
Figure 3. Schematic of how the targeted nanoparticles
function. (a) Nanoparticles are assembled from the four
components (see Figure 2). (b) Aqueous solutions of
nanoparticles are infused into patients. (c) The nano-
particles circulate in the blood of the patient and escape
via the “leaking” blood vessels in tumors. (d) Nano-
particles penetrate though the tumor and enter into cells
by receptor-mediated endocytosis (transmission elec-
tron micrograph of 50 nm nanoparticles entering a
cancer cell). Note that the nanoparticles enter and are
initially located in vesicles within the cell and must
escape and disassemble to deliver their payload. (e)
Targeted nanoparticles can have numerous interactions
(e.g., Tf with its receptor) on the surface of the cancer
cell that then stimulate entrance into the cell.
reviews DaVis
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to exhibit a “proton sponge” effect, since they have titratable
amine groups (pKa values in the range of 4-7) and have the
ability to buffer the pH changes as endocytic vesicles
acidify.13 The concept involves the buffering of endocytic
vesicles, their swelling due to osmotic pressure increases,
and ultimately vesicle rupture to release its contents. In
attempts to exploit this proposed pathway of release, several
publications have shown that histidylated or imidazolated
polycations provided substantial gene delivery over their
parent polymers.14,15 Pun (formerly Hwang) first conjugated
histidine to the ends of the CDP and showed enhanced gene
delivery over the CDP without end group modification.16
Subsequently, the end groups were modified to imidazole
groups.4,12 The addition of the imidazole termini did provide
buffering of endocytic vesicles in live cells.17 Investigations
into the underlying processes of imidazole-modified CDP
behavior to give enhanced delivery efficacies revealed that
there are numerous functions occurring simultaneously in
addition to the buffering and endocytic vesicle escape.18
Thus, the precise mechanisms leading to enhanced delivery
efficiencies remain elusive. However, there is no question
that the addition of imidazole to the CDP does enhance
delivery efficacy (whether plasmid or siRNA18). The final
CDP used for in vivo work does contain imidazole end group
modifications as illustrated in Figure 2a.
Steric Stabilization, AD-PEG. Nanoparticles that are
polycation-nucleic acid composites are known to be unstable
in biological fluids such as blood. One method of preventing
self-aggregation and undesired interactions with nonself
entities in biological fluids is to employ steric stabilization.
Polythethylene glycol (PEG) has been conjugated to different
non-viral delivery carriers, and the resulting PEGylated
particles have demonstrated increased salt and serum stabil-
ity. A difficulty with directly PEGylating a polycation is that
the PEG can interfere with the binding to the nucleic acid
(this is particularly important with siRNA). While there is a
significant amount of PEGylation technology that is available,
it all relies upon covalent attachment of the PEG to the
carrier. We developed a new methodology for steric stabi-
lization with PEG polymers that exploits the presence of the
cyclodextrin in the CDP.
The concept of providing steric stabilization to the
CDP-nucleic acid nanoparticle involves the fact that cy-
clodextrins can form inclusion complexes with small mol-
ecules (for a review on inclusion complexes and their uses
in pharmaceutical applications, see ref 5). Adamantane (AD)
has one of the highest association constants with beta-
cyclodextrin (on the order of 104-105 M-1 for adamantane
carboxylate19). A molecular conjugate of AD and PEG can
be formed by reacting one end of the PEG with AD. The
AD in the AD-PEG conjugate can form an inclusion complex
with the beta-cyclodextrin (Figure 5) on the surface of the
nanoparticle in order to decorate the surface with AD-PEG
to provide steric stabilization (see schematics in Figures 2,
3, and 5).19 This formulation is the first to create steric
stabilization on a nanoparticle with PEG via noncovalent
interactions. In order to provide stabilization in 150 mM salt,
the molecular weight of the PEG needed to be at least 5000.19
Lower molecular weight PEGs were not able to provide
complete stabilization at a mole ratio of cyclodextrin to AD
of 1 to 1, and higher molecular weight PEGs were not
investigated.19,20 Additionally, the AD-PEG conjugate can
be prepared such that it includes charge. That is, an anionic
region can be placed between the AD and the PEG, for
(13) Behr, J. P. The proton sponge: A trick to enter cells that viruses
did not exploit. Chimia 1997, 51, 34–36.
(14) Putnam, D.; Gentry, C.; Pack, D.; Langer, R. Polymer-based gene
delivery with low cytotoxicity by a unique balance of side-chain
termini. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 1200–1205.
(15) Midoux, P.; Monsigny, M. Efficient Gene Transfer by Histidylated
Polylysine/pDNA Complexes. Bioconjugate Chem. 1999, 10, 406–
411.
(16) Hwang, S. Rational design of a new class of cyclodextrin-
containing polymers for gene delivery. Ph.D. Thesis in Chemical
Engineering, California Institute of Technology, Pasadena, CA,
2001.
(17) Kulkarni, R. P.; Mishra, S.; Fraser, S. E.; Davis, M. E. Single
Cell Kinetics of Intracellular, Non-Viral, Nucleic Acid Delivery
Vehicle Acidification and Trafficking. Bioconjugate Chem. 2005,
16, 986–994.
(18) Mishra, S.; Heidel, J. D.; Webster, P.; Davis, M. E. Imidazole
End Groups on a Linear, Cyclodextrin-Containing Polycation
Produce Enhanced Gene Delivery via Multiple Processes. J.
Controlled Release 2006, 116, 179–191.
Figure 4. Schematic of linear, water-soluble cyclodextrin-
containing polymers. (a) Generalized structure of poly-
mers where A represents a segment of the polymer that
comes from one comonomer (typically containing the
cyclodextrin), B represents a segment of the polymer
that comes from the other comonomer, C is the charge
center, and S is the spacer between A and C. (b)
Specific example of a polymer with labeled A, B, C, and
S. Adapted with permission from ref 12. Copyright 2004
CRC Press.
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example, and those conjugates can be used alone or in
combination with AD-PEG to tune the surface zeta potential
of the nanoparticles. Using a 1:1 ratio of cyclodextrin to AD
in the formulation but a combination of AD-PEG and
AD-anionic charge-PEG, the zeta potential of the formu-
lated nanoparticles could be tuned from 15 mV at 100% AD-
PEG to -25 mV at 0% AD-PEG.12
Targeting Agent, AD-PEG-R. The PEGylation of nano-
particles to provide steric stabilization for systemic admin-
istration also greatly reduces the ability of the nanoparticles
to interact with the surfaces of cells. In order to engage cell
surface receptors for receptor-mediated endocytosis, targeting
ligands can be added to the nanoparticles. When PEGylating
the CDP-nucleic acid nanoparticles with AD-PEG, the
cellular uptake and intracellular trafficking were significantly
affected over non-PEGylated nanoparticles.21 Thus, to add
a targeting ligand for enhancing specific cellular uptake,
another molecular conjugate was developed: AD-PEG-R. Just
like with AD-PEG, the AD-PEG-R conjugate can decorate
the surface of the CDP-nucleic acid nanoparticle to give a
controlled number of targeting ligands (R). Targeting ligands
are conjugated to the opposite end of the PEG from the AD
(molecular weight of the PEG remained 5000). The length
of the PEG allows the targeting agent to be located at the
exterior surface of the PEGylated nanoparticle, and the PEG
spacer provides sufficient flexibility and distance from the
surface of the CDP-nucleic acid core to allow for binding
to cell surface receptors with good affinity.20,22 In fact,
several Tf molecules on the surface of the nanoparticles can
provide multivalent binding to cell surfaces that have high
TfR density.20 A variety of targeting ligands have been
explored. For example, small molecules such as galactose
(for targeting hepatocytes)4,12,19 and proteins such as trans-
ferrin (for targeting cancer cells)20,22 and antibody fragments
(see below) have been reported for this system. The targeting
ligand that has been investigated in the greatest detail is Tf.
The amount of TfR is known to be elevated on the surfaces
of malignant cells of many types. Thus, it provides a cell
surface receptor that can be targeted for a variety of cancers.
Additionally, GMP human Tf is now commercially available
(from Mebiopharm in Japan).
Two-Vial Formulation
The formulation of the three delivery system components
(CDP, AD-PEG, AD-PEG-R) with a nucleic acid to give a
targeted nanoparticle was accomplished as follows. Shortly
after the delivery system was developed, we recognized that
the nanoparticles could be formulated by adding all the
components together at one time (schematically illustrated
in Figure 2b). The delivery components were placed in one
vial and the nucleic acid in a second vial. When the two
solutions (same volumes) are mixed, the nanoparticles
self-assemble.12,20 What is intriguing about this formulation
is that the assembly can give nanoparticles at very high
concentrations. These self-assembled formulations can occur
at nucleic acid concentrations in the mg nucleic acid/mL
range.12,20 A typical formulation involves a 3:1 charge ratio
of polymer positive charge to nucleic acid negative charge.
This ratio insures that all the nucleic acid is contained within
nanoparticles. The nanoparticles have approximately a 1:1
charge ratio,20 so excess CDP is in solution. Also, since a
1:1 mol ratio between the cyclodextrin and the AD from the
total AD-PEG and AD-PEG-R is used, there is excess AD-
PEG and AD-PEG-R in solution. Complete compositional
analyses of these nanoparticles have been published using
siRNA and AD-PEG-Tf.20 The formulation gave a 70 nm
diameter nanoparticle that contained ∼10 000 CDP mol-
ecules, ∼2000 siRNA molecules (19 base pair duplexes with
2 base overhangs on either end), ∼4000 AD-PEG, and ∼100
AD-PEG-Tf.20 The amount of Tf can be tuned from zero to
about 5 mol % of the total AD-PEG before Tf-Tf induced
aggregation of the particles occurs.20
Two features of the self-assembly formulation warrant
further discussion. First, the nanoparticle diameters of CDP
formulations with siRNA, pDNA, and calf thymus DNA
(CT-DNA) all increase with nucleic acid concentration
(exceeding 100 nm) when AD-PEG is not included at the
time of formulation.20 However, when AD-PEG is included,
the nanoparticle diameters remain constant, independent of
nucleic acid concentration at 60-80 nm.20 Thus, the AD-
PEG changes the assembly processes that are occurring and
provides a formulation that provides highly concentrated
nanoparticles by simple mixing. Second, if the AD-PEG
conjugates were providing stability by only the inclusion
complex interactions, then the stabilization should disappear
upon dilution of the nanoparticles (as would occur upon
injection into an animal or human). After years of investiga-
(19) Pun, S. H.; Davis, M. E. Development of a Non-Viral Gene
Delivery Vehicle for Systemic Application. Bioconjugate Chem.
2002, 13, 630–639.
(20) Bartlett, D. W.; Davis, M. E. Physicochemical and Biological
Characterization of Targeted, Nucleic Acid-Containing Nanopar-
ticles. Bioconjugate Chem. 2007, 18, 456–468.
(21) Mishra, S.; Webster, P.; Davis, M. E. PEGylation Significantly
Affects Cellular Uptake and Intracellular Trafficking of Non-viral
Gene Delivery Particles. Eur. J. Cell Biol. 2004, 83, 97–111.
(22) Bellocq, N. C.; Pun, S. H.; Jensen, G. S.; Davis, M. E. Transferrin-
Containing, Cyclodextrin Polymer-Based Particles for Tumor-
Targeted Gene Delivery. Bioconjugate Chem. 2003, 14, 1122–
1132.
Figure 5. Schematic representations of the adamantane-
PEG inclusion complex formation with the cyclodextrin
(left) and the PEG-PEG interactions when the AD-PEGs
are localized on the surface of the nanoparticles (right).
reviews DaVis
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tion, the reason for the lack of dissociation upon dilution of
the AD-PEG from the nanoparticles was determined. By
using isothermal titration calorimetry (ITC), the thermody-
namics of the interactions between the AD-PEG and either
an individual cyclodextrin, a CDP strand, or an assembled
CDP-siRNA nanoparticle were measured. The change in
enthalpy from binding between the AD-PEG and the three
forms of CD mentioned showed that there was a significant
increase in the energy of stabilization only when the AD-
PEG was binding to the nanoparticle.20 We hypothesized
that this increase in stabilization energy was from favorable
interactions between the PEG chains that were closely
associated on the surface of the nanoparticle (see Figure 5
for schematic).
As the molecular weight of the PEG was decreased, this
stabilization energy declined. Thus, if our hypothesis is
correct, then the self-assembly process can be understood
further. That is, in the solution of the delivery components,
the AD-PEG (and AD-PEG-R) is interacting with the CDP
but those interactions are driven entirely by the inclusion
complex formation and are weak. When the nucleic acid is
added, the multivalent electrostatic interactions between the
CDP and the nucleic acid are sufficiently strong to provide
for CDP-nucleic acid assembly into nanoparticles (exclude
AD-PEG components from the interior). As the nanoparticles
are forming, the AD-PEG components form inclusion
complexes with surface cyclodextrins, and when they do,
then the configuration is stabilized by the extra stabilization
energy obtained from the lateral interactions of the high
density of PEG organized on the surface of the nanoparticle.
Upon dilution, this extra energy of stabilization is the key
energy inhibiting disassembly. There is clear evidence that
the AD-PEG-Tf remains on the nanoparticles as the effects
of the Tf are observable in animals (discussed below).
When dealing with self-assembling systems, there is
concern about their stability under “working” conditions. For
the present case, the nanoparticles need to be stable in the
circulation. Thus, we tested their ability to self-assemble
under working conditions as follows. The delivery compo-
nents were injected iv into the tail vein of mice, and then 1
min later siRNA was injected iv into the same tail vein. A
few minutes later, blood was collected and serum run on a
gel to determine whether the siRNA had assembled with the
CDP in the circulation. Also, the order of injection was
reversed. The data obtained are shown in Figure 6. The
results clearly show that the siRNA and the CDP self-
assemble in the circulation of the mouse. Given that the
components self-assemble under “working” conditions, the
likelihood that they would disassemble in the circulation is
low. In fact, plasma/serum samples collected from numerous
animal experiments have not revealed any free siRNA.
In Vivo Delivery of DNAzymes and pDNA in
Mice
Initial animal experiments using the CDP, AD-PEG, and
AD-PEG-Tf delivery components utilized two different types
of nucleic acids, namely, DNAzymes23 and pDNA.24 Results
from those two investigations were consistent with one
another and provided the basis for siRNA delivery in vivo
(next section).
Intravenous injections of nanoparticles containing Cy-3-
labeled DNAzymes were monitored by whole animal fluo-
rescence imaging of tumor-bearing mice.23 Nanoparticles that
lacked AD-PEG or AD-PEG-Tf collected in the lungs,
presumably due to aggregation. However, when nanoparticles
contained AD-PEG, there was no fluorescence observed in
the lungs. These results strongly suggest that the PEGylated
particles do not aggregate in circulation. Tumor site fluo-
rescence was obtained with nanoparticles containing AD-
PEG and those with AD-PEG + AD-PEG-Tf. However,
intracellular delivery within the tumor was only observed
with the formulation that contained the AD-PEG-Tf.
Intravenous injections of nanoparticles containing pDNA
coding for the p53 gene were studied in nude mice bearing
PC3 tumors (TfR positive and p53 null).24 The nanoparticles
were formulated with either AD-PEG or AD-PEG + AD-
PEG-Tf. By using PCR methods, the biodistribution of the
plasmid was determined. It was observed that the amount
(23) Pun, S. H.; Tack, F.; Bellocq, N. C.; Cheng, J.; Grubbs, B. H.;
Jensen, G. S.; Davis, M. E.; Brewster, M.; Janicot, M.; Janssens,
B.; Floren, W.; Bakker, A. Targeted delivery of RNA-cleaving
DNA enzyme (DNAzyme) to tumor tissue by transferring-
modified, cyclodextrin-based particles. Cancer Biol. Ther. 2004,
3, 641–650.
(24) Bellocq, N. C.; Davis, M. E.; Engler, H.; Jensen, G. S.; Liu, A.;
Machemer, T.; Maneval, D. C.; Quijano, E.; Pun, S. H.; Schluep,
T.; Wen, S. Transferrin-targeted, cyclodextrin polycation-based
gene vector for systemic delivery. Mol. Ther. 2003, 7, S290.
Figure 6. Self-assembly test in the circulation of mice.
The delivery components (CDP, AD-PEG, AD-PEG-Tf)
are denoted Excip. When the siRNA alone is injected iv
into mice, free siRNA is observed on a gel from plasma
collected 3 min after injection (last lane). When the
Excip are injected and then 1 min later the siRNA
injected (or the reverse order), plasma collected at 3
min after the first injection shows no free siRNA (lanes
3 and 4 from the left) and bands indicative of
formulated particles (injected formulated particles are in
the next to the last lane) are obtained. The mouse
experiments were conducted by B. Mack at Caltech,
and the gel run by J. Liu at Calando Pharmaceuticals.
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of the plasmid in the tumor was ∼10% of the injected dose
in the best cases and that there were no differences in the
amounts of plasmid localized in the tumors when using
nanoparticles that did or did not contain the AD-PEG-Tf.
However, using RT-PCR, the amount of mRNA from the
delivered p53 gene was measured. No mRNA was observed
from the formulation that did not have Tf, while the Tf-
containing formulation did yield p53 mRNA.
The results of these two studies showed that amounts of
tumor localization of the nanoparticles were independent of
the presence of the targeting ligand (Tf). However, in both
cases, the data are consistent with the Tf ligand providing
greater tumor cell uptake (directly observed in the case of
the DNAzyme and implied by the presence of the mRNA
for the case with the pDNA). Additionally, it is clear that
the nanoparticles need to be PEGylated to provide for
circulation without significant lung accumulation.
Movement to siRNA Delivery
The discovery of RNAi and more specifically the dem-
onstration that siRNA could function in mammalian cells
without eliciting an immune response opened the pathway
for creating human therapeutics with siRNA. Potent siRNA
against almost any gene target can be found. However, a
major hurdle to the creation of human therapeutics with
siRNA is the delivery problem. Thus, it is not surprising
that the initial clinic applications of siRNA involve local
delivery. Several companies have announced programs to
create systemically delivered siRNA, and Calando Pharma-
ceuticals was the first to enter the clinic with their targeted
delivery of siRNA (CALAA-01) for cancer in 2008. While
the exact nature of CALAA-01 has not been reported, it is
similar to the delivery system outlined here (Figures 2 and
3). Work contributing to the development of CALAA-01 is
presented in this section.
Given the success of the CDP-based delivery system for
DNAzymes and pDNA, when siRNA was discovered, the
CDP-based delivery system was investigated for use with
siRNA. Since siRNA does not need to be transported into
the nucleus, the intracellular delivery problem is actually less
complicated than with pDNA.
Naked siRNA is quickly degraded by serum nucleases.
Thus, numerous studies employing siRNA utilize chemical
modifications that increase its stability. However, clinical
studies with naked siRNA do not always use chemically
modified siRNA. Bartlett and Davis showed that the gene
inhibition kinetics of unmodified and nuclease-stabilized
siRNA were essentially the same when electroporated into
cells.25 Thus, the intracellular half-life of gene inhibition does
not appear to be a function of nuclease stability. These
authors hypothesized that the stabilization advantages of
nuclease-stabilized siRNA originate primarily from the
effects prior to and during internalization before the siRNA
can interact with the intracellular RNAi machinery.25 A more
important factor that determines the gene inhibition half-
life is the cell doubling time.26 Both in vitro and in vivo
data demonstrate that dilution due to cell division and not
intracellular siRNA stability governs the duration of gene
silencing.26 Therefore, the use of a delivery system that
protects the siRNA from degradation prior to intracellular
release should be able to function with siRNA that is not
chemically modified although such formulations may produce
an innate immune response.
Shortly after the discovery of siRNA function in mam-
malian cells, there were reports of immune responses in cell
cultures. However, Heidel and co-workers showed that naked
siRNA could be administered systemically to mice without
inducing an interferon response.27 There are a number of
Toll-like receptors that are located on different cell types
and even at different locations (on cell surfaces or in the
endosome) on various cell types (TLR-3 is located both on
the cell surface and intracellularly in human fibroblasts but
remains intracellular in other cell types such as monocyte-
derived immature dendritic cells). Thus, the biodistribution
and cellular uptake of the siRNA could likely affect whether
innate immune responses are stimulated in animals and
humans. Judge et al. showed that non-viral delivery vehicles
(both lipid-based and polymer-based) could induce interferon
and inflammatory cytokine responses in mice when formu-
lated with siRNA.28 This group also reported that selective
incorporation of 2′-O-methyl modifications of the RNA
strands could eliminate these responses in mice.29
The initial demonstration of CDP-based delivery system
formulated with siRNA (not chemically modified) utilized
a disseminated murine model of Ewing’s sarcoma.30 siRNA
targeting the breakpoint of the EWS-FLI1 fusion gene was
shown to inhibit the gene product in vitro and that this
inhibition provided an antiproliferative effect. TC71 cells
(TfR positive, EWS-FLI1 positive) constitutively expressing
luciferase were injected into mice, and their proliferation was
monitored by in vivo bioluminescence imaging. The treat-
ment groups investigated were (i) injection solution (D5W),
(ii) naked siRNA, (iii) full formulation (illustrated in Figure
(25) Bartlett, D. W.; Davis, M. E. Effect of siRNA nuclease stability
on the in vitro and in vivo kinetics of siRNA-mediated gene
silencing. Biotechnol. Bioeng. 2007, 97, 909–921.
(26) Bartlett, D. W.; Davis, M. E. Insights into the kinetics of siRNA-
mediated gene silencing from live-cell and live-animal biolumi-
nescent imaging. Nucleic Acids Res. 2006, 34, 322–333.
(27) Heidel, J. D.; Hu, S; Liu, X. F.; Triche, T. J.; Davis, M. E. Lack
of Interferon Response in Animals to Naked siRNA. Nat.
Biotechnol. 2004, 22, 1579–1582.
(28) Judge, A. D.; Sood, V.; Shaw, J. R.; Fang, D.; McClintock, K.;
MacLachlan, I. Sequence-independent stimulation of the mam-
malian innate immune response by synthetic siRNA. Nat. Bio-
technol. 2005, 23, 457–462.
(29) Judge, A. D.; Bola, G.; Lee, A. C. H.; MacLachlan, I. Design of
noninflammatory synthetic siRNA mediating potent gene silencing
in vivo. Mol. Ther. 2006, 13, 494–505.
(30) Hu-Lieskovan, S.; Heidel, J. D.; Bartlett, D. W.; Davis, M. E.;
Triche, T. J. Sequence-specific knockdown of EWS-FLI1 by
targeted, non-viral delivery of siRNA inhibits tumor growth in a
murine model of metastatic Ewing’s sarcoma. Cancer Res. 2005,
65, 8984–8992.
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2) with a control siRNA, (iv) full formulation with the anti-
EWS-FLI1 siRNA, and (v) formulation without the AD-
PEG-Tf of the anti-EWS-FLI1 siRNA. Only formulation (iv)
revealed any antitumor effects (and tumor inhibition of EWS-
FLI1 mRNA). Further studies indicated that no innate
immune responses were obtained from any of these formula-
tions. Thus, this work provided evidence to show that the
correct sequence and the targeting agent were both necessary
for biological efficacy. Of importance was the fact that the
control sequence contained a known immunostimulatory
motif when used with lipid-based delivery systems. Thus,
the CDP-based delivery system did not elicit innate immune
responses even with known immunostimulatory sequences.
Further investigations with the CDP-based delivery system
have been reported. Bartlett et al. showed via in vivo
multimodal imaging (PET and bioluminescence) the kinetics
of the biodistribution and gene inhibition function of the
targeted and nontargeted versions of the nanoparticles.31
Interestingly, like with the delivery of the pDNA (p53
gene),24 the amount of siRNA reaching the tumor was the
same for the Tf targeted and nontargeted siRNA-containing
nanoparticles.31 The kinetics of the biodistribution were
unchanged between targeted and untargeted nanoparticles.
However, the luciferase gene inhibition was significantly
greater for the Tf targeted nanoparticles. Thus, the primary
effect of the Tf targeting ligand is to enhance tumor cell
uptake not to change the amount localized in the tumor
tissue.31 This conclusion has been obtained with a lipid-based
delivery system as well.32 That is not to say that a
nontargeted nanoparticle does not enter tumor cells, but rather
that the targeted version of the nanoparticle should always
outperform the nontargeted version. Bartlett and Davis have
shown this using a potent siRNA against ribonucleo-
tide reductase subunit 2 (RRM2) in a murine tumor model.33
The likely reason for the lack of antitumor efficacy with the
nontargeted EWS-FLI1 siRNA was that the siRNA used in
that study was not highly potent.30 Given the results from
these studies, the CDP-based delivery system was translated
into clinical use as described next.
CALAA-01
CALAA-01 is an experimental therapeutic that employs
the CDP-based delivery system to formulate siRNA against
ribonucleotide reductase subunit 2 (RRM2). This experi-
mental therapeutic was developed under the direction of Dr.
Jeremy Heidel at Calando Pharmaceuticals.34 CALAA-01
employs Tf as the targeting agent, and the siRNA is not
chemically modified. The clinical material is a two-vial
formulation as illustrated in Figure 2. A potent siRNA against
RRM2 was developed that exhibits significant antiprolifera-
tive activity in a broad spectrum of cancer types of human,
mouse, rat, and monkey.35 The RRM2 sequence shows
complete target site homology in mouse, rat, and monkey,
and this greatly assisted in the translation of this siRNA into
the clinic. The RRM2 gene product is an established cancer
target, and reviews on the history of this antitumor target
are available.36 A pilot safety study in nonhuman primates
has been published.37 This study was the first to show that
multidosing of siRNA could be safely accomplished in a
nonhuman primate. No complement activation and liver
toxicities were observed at any dose level. When adminis-
tered at 3 and 9 mg siRNA/kg, the nanoparticles were well
tolerated. However, at 27 mg siRNA/kg, elevated levels of
blood urea nitrogen and creatinine were observed, indicating
mild kidney toxicity (was reversible). Additionally, at this
dose level, IL-6 levels were increased. Multiple administra-
tions spanning a time frame of 17-18 days (dosing on days
1, 4, and 7 followed by dosing on day 19 for assessing
antibody formulation and possible effects on PK) allowed
for assessment of anti-nanoparticle antibodies. Low titer,
nonclearing (no changes in PK) antibodies to the human Tf
on the nanoparticles were obtained. The antibodies were not
against the PEGylated nanoparticles. This is important, as
clearing antibody generation in humans has been observed
with PEGylated liposomes. In total, the multiple, systemic
doses of the targeted nanoparticles containing the nonchemi-
cally modified siRNA were safely administered to nonhuman
primates. Antitumor efficacy has been observed in mouse
models with doses of 2.5-5.0 mg siRNA/kg mouse.30,31,33,38
Using body surface area normalizations, these dose levels
(31) Bartlett, D. W.; Su, H.; Hildebrandt, I. J.; Weber, W. A.; Davis,
M. E. Impact of tumor-specific targeting on the biodistribution
and efficacy of siRNA nanoparticles measured by multimodality
in vivo imaging. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 15549–
15554.
(32) Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.;
Hong, K.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W.
Antibody targeting of long-circulating lipidic nanoparticles does
not increase tumor localization but does increase internalization
in animal models. Cancer Res. 2006, 66, 6732–6740.
(33) Bartlett, D. W.; Davis, M. E. Impact of tumor-specific targeting
and dosing schedule on tumor growth inhibition after intravenous
administration of siRNA-containing nanoparticles. Biotechnol.
Bioeng. 2008, 99, 975–985.
(34) Heidel, J. D. Linear cyclodextrin-containing polymers and their
use as delivery agents. Expert Opin. Drug DeliVery 2006, 3, 641–
646.
(35) Heidel, J. D.; Liu, J. Y. C.; Yen, Y.; Zhou, B.; Heale, B. S. E.;
Rossi, J. J.; Bartlett, D. W.; Davis, M. E. Potent siRNA Inhibitors
of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Prolif-
eration In Vitro and In Vivo. Clin. Cancer Res. 2007, 13, 2207–
2215.
(36) Cerqueira, N. M. F. S. A.; Pereira, S.; Fernandes, P. A.; Ramos,
M. J. Overview of ribonucleotide reductase inhibitors: an appeal-
ing target in anti-tumor therapy. Curr. Med. Chem. 2005, 12,
1283–1294.
(37) Heidel, J. D.; Yu, Z.; Liu, J. Y. C.; Rele, S. M.; Liang, Y.; Zeidan,
R. K.; Kornbrust, D. J.; Davis, M. E. Administration in non-human
primates of escalating intravenous doses of targeted nanoparticles
containing ribonucleotide reductase sub-unit M2 siRNA. Proc.
Natl. Acad. Sci. U.S.A. 2007, 104, 5715–5721.
(38) Chuang, H. F.; Heidel, J. D.; Liu, J. Y. C.; Zeidan, R. K.; Liang,
Y.; Rele, S.; Davis, M. E. siRNA delivery by RONDELTM
(trademark) a cyclodextrin-polymer based delivery system: from
benchtop to the clinic. Abstract, AIChE meeting, 2008.
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translate to 0.6-1.2 mg siRNA/kg monkey. Thus, the
predicted therapeutic window is quite large based on these
data.
CALAA-01 was used to treat the first patient in a phase I
clinical trial in May of 2008. The trial is a safety study
treating adults with solid tumors who are refractory to
standard-of-care therapies. CALAA-01 is administered via
a 30 min iv infusion on days 1, 3, 8, and 10 of a 21-day
cycle. Further details of the trial can be found at www.
clinicaltrials.gov. As of this writing (end of 2008), dose
escalations have occurred and the trial is proceeding.
CALAA-01 is the first targeted delivery of siRNA in
humans. Comparisons to other nontargeted and targeted
experimental and approved therapeutics can be found
elsewhere.39,40 The treatment of patients with CALAA-01
ushers in a new era of targeted experimental therapeutics.
Other formulated siRNA therapeutics are sure to follow
CALAA-01, and it will be interesting to monitor the progress
of these experimental treatments over upcoming years.
Beyond CALAA-01 with CDP-Targeted
Delivery of siRNA
In addition to CALAA-01, Calando Pharmaceuticals has
announced another siRNA product denoted CALAA-02.38
CALAA-02 uses the same delivery system as CALAA-01,
but the siRNA now targets HIF-2alpha (another cancer
target). Hotchkiss and his colleagues working with Heidel
at Calando Pharmaceuticals have used the CDP delivery
system to coadminister siRNA against Bim and PUMA in a
mouse model of sepsis.41 Effective administration of the
antiapoptotic siRNA to lymphocytes reversed the immune
cell depletion normally observed in sepsis.
My group at Caltech continues to work with the CDP-
based delivery system. Our current efforts involve the
development of antibody fragment (Fab and F(ab′)2) targeting
agents.42 Fab-containing nanoparticles (Fab-PEG-AD) can
be formulated and show multivalency when binding to cell
surfaces. In vivo work in mouse models is proceeding at
this time.
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